| [1] |
Badwelan M, Muaddi H, Ahmed A, et al. Oral squamous cell carcinoma and concomitant primary tumors, what do we know? A review of the literature[J]. Curr Oncol, 2023, 30(4): 3721-3734.
doi: 10.3390/curroncol30040283
pmid: 37185396
|
| [2] |
Panarese I, Aquino G, Ronchi A, et al. Oral and Oropharyngeal squamous cell carcinoma: Prognostic and predictive parameters in the etiopathogenetic route[J]. Expert Rev Anticancer Ther, 2019, 19(2): 105-119.
doi: 10.1080/14737140.2019.1561288
|
| [3] |
Ng JH, Iyer NG, Tan MH, et al. Changing epidemiology of oral squamous cell carcinoma of the tongue: A global study[J]. Head Neck, 2017, 39(2): 297-304.
doi: 10.1002/hed.v39.2
|
| [4] |
Mody MD, Rocco JW, Yom SS, et al. Head and neck cancer[J]. Lancet, 2021, 398(10318): 2289-2299.
doi: 10.1016/S0140-6736(21)01550-6
pmid: 34562395
|
| [5] |
侯泽宇, 唐金茹, 李龙江. 口腔鳞状细胞癌发生、发展过程中细胞周期调控因子的研究进展[J]. 口腔颌面外科杂志, 2023, 33(2): 119-122.
doi: 10.3969/j.issn.1005-4979.2023.02.011
|
| [6] |
Linsen SS, Gellrich NC, Krüskemper G. Age- and localization-dependent functional and psychosocial impairments and health related quality of life six months after OSCC therapy[J]. Oral Oncol, 2018, 81: 61-68.
doi: S1368-8375(18)30152-0
pmid: 29884415
|
| [7] |
Meier JK, Schuderer JG, Zeman F, et al. Health-related quality of life: A retrospective study on local vs. microvascular reconstruction in patients with oral cancer[J]. BMC Oral Health, 2019, 19(1): 62.
doi: 10.1186/s12903-019-0760-2
pmid: 31029131
|
| [8] |
秦星. CAFs源性IL-6诱导的骨桥蛋白调控口腔鳞癌生长和转移[D]. 上海: 上海交通大学, 2019.
|
| [9] |
李蕾, 李晓东, 庄乾伟, 等. 超声热疗联合TPF化疗治疗19例老年晚期口腔鳞癌的疗效分析[J]. 上海口腔医学, 2021, 30(5): 543-547.
|
| [10] |
Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase Ⅲ trial: Postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck[J]. Int J Radiat Oncol Biol Phys, 2012, 84(5): 1198-1205.
doi: 10.1016/j.ijrobp.2012.05.008
|
| [11] |
Jadhav KB, Nagraj SK, Arora S. miRNA for the assessment of lymph node metastasis in patients with oral squamous cell carcinoma: Systematic review and metanalysis[J]. J Oral Pathol Med, 2021, 50(4): 345-352.
doi: 10.1111/jop.13134
pmid: 33220092
|
| [12] |
Liu X, Ma XR, Li HY, et al. LINC00472 suppresses oral squamous cell carcinoma growth by targeting miR-455-3p/ELF3 axis[J]. Bioengineered, 2022, 13(1): 1162-1173.
doi: 10.1080/21655979.2021.2018092
pmid: 35258410
|
| [13] |
Wang ZK, Guan WZ, Ma YF, et al. microRNA-191 regulates oral squamous cell carcinoma cells growth by targeting PLCD1 via the Wnt/β-catenin signaling pathway[J]. BMC Cancer, 2023, 23(1): 668.
doi: 10.1186/s12885-023-11113-9
|
| [14] |
He SQ, Zhang W, Li X, et al. Oral squamous cell carcinoma (OSCC)-derived exosomal miR-221 targets and regulates phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) to promote human umbilical vein endothelial cells migration and tube formation[J]. Bioengineered, 2021, 12(1): 2164-2174.
doi: 10.1080/21655979.2021.1932222
pmid: 34098850
|
| [15] |
Jadhav KB, Shah V, Chauhan N, et al. Expression of microRNA-21 in saliva and tumor tissue of patients with oral squamous cell carcinoma: A predictor of cervical lymph node metastasis[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2022, 133(1): 60-69.
doi: 10.1016/j.oooo.2021.07.012
|
| [16] |
Song QH, Sui JZ, Yang YX, et al. Fructose-1, 6-bisphosphatase 1 in cancer: Dual roles, mechanistic insights, and therapeutic potential: A comprehensive review[J]. Int J Biol Macromol, 2025, 293: 139273.
doi: 10.1016/j.ijbiomac.2024.139273
|
| [17] |
Chen MQ, Zhang JB, Li N, et al. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer[J]. PLoS One, 2011, 6(10): e25564.
doi: 10.1371/journal.pone.0025564
|
| [18] |
Li M, Wang Z, Tao JJ, et al. Fructose-1, 6-bisphosphatase 1 dephosphorylates and inhibits TERT for tumor suppression[J]. Nat Chem Biol, 2024, 20(11): 1505-1513.
doi: 10.1038/s41589-024-01597-2
|
| [19] |
Yuan YM, Wang JZ, Huang LQ, et al. Bioinformatics identifica-tion of prognostic genes and potential interaction analysis in renal cell carcinoma[J]. Transl Cancer Res, 2023, 12(4): 774-783.
doi: 10.21037/tcr
|
| [20] |
Qattan AT, Radulovic M, Crawford M, et al. Spatial distribution of cellular function: The partitioning of proteins between mitochondria and the nucleus in MCF7 breast cancer cells[J]. J Proteome Res, 2012, 11(12): 6080-6101.
doi: 10.1021/pr300736v
pmid: 23051583
|
| [21] |
Peng X, Ma LS, Chen X, et al. Inhibition of FBP1 expression by KMT5A through TWIST1 methylation is one of the mechanisms leading to chemoresistance in breast cancer[J]. Oncol Rep, 2024, 52(2): 110.
doi: 10.3892/or
|
| [22] |
Song MQ, Bode AM, Dong ZG, et al. AKT as a therapeutic target for cancer[J]. Cancer Res, 2019, 79(6): 1019-1031.
doi: 10.1158/0008-5472.CAN-18-2738
pmid: 30808672
|
| [23] |
Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer[J]. Cancer Treat Rev, 2004, 30(2): 193-204.
doi: 10.1016/j.ctrv.2003.07.007
pmid: 15023437
|
| [24] |
Khezri MR, Jafari R, Yousefi K, et al. The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions[J]. Exp Mol Pathol, 2022, 127: 104787.
doi: 10.1016/j.yexmp.2022.104787
|
| [25] |
Liu R, Chen YW, Liu GZ, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers[J]. Cell Death Dis, 2020, 11(9): 797.
doi: 10.1038/s41419-020-02998-6
pmid: 32973135
|
| [26] |
Shen T, Yang TR, Yao MF, et al. BTC as a novel biomarker contributing to EMT via the PI3K-AKT pathway in OSCC[J]. Front Genet, 2022, 13: 875617.
doi: 10.3389/fgene.2022.875617
|
| [27] |
Wang H, Wang L, Zhou XC, et al. OSCC exosomes regulate miR-210-3p targeting EFNA3 to promote oral cancer angiogenesis through the PI3K/AKT pathway[J]. Biomed Res Int, 2020, 2020: 2125656.
doi: 10.1155/bmri.v2020.1
|
| [28] |
Xu SQ, Qin X, Liang JL, et al. Harnessing tetrahedral framework nucleic acids for enhanced delivery of microRNA-149-3p: A new frontier in oral squamous cell carcinoma therapy[J]. Cell Prolif, 2024, 57(8): e13637.
doi: 10.1111/cpr.v57.8
|